Elizabeth Alli

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
    Elizabeth Alli
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, Center for Clinical Sciences Research, Stanford, CA 94305, USA
    BMC Pharmacol 11:7. 2011
  2. doi request reprint Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol
    Elizabeth Alli
    Stanford University School of Medicine, Department of Medicine Oncology, 269 Campus Drive, Stanford, CA 93405, USA
    DNA Repair (Amst) 11:522-4. 2012
  3. pmc Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin
    Kedar Hastak
    Division of Oncology, Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 70:7970-80. 2010
  4. pmc Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase
    Elizabeth Alli
    Department of Medicine Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Cancer Res 69:3589-96. 2009
  5. doi request reprint A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
    Shaveta Vinayak
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Breast Cancer Res Treat 142:389-98. 2013

Collaborators

Detail Information

Publications5

  1. pmc Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
    Elizabeth Alli
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, Center for Clinical Sciences Research, Stanford, CA 94305, USA
    BMC Pharmacol 11:7. 2011
    ..BRCA1 plays a role in multiple DNA repair pathways, and thus, when mutated, results in sensitivity to certain DNA damaging drugs...
  2. doi request reprint Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol
    Elizabeth Alli
    Stanford University School of Medicine, Department of Medicine Oncology, 269 Campus Drive, Stanford, CA 93405, USA
    DNA Repair (Amst) 11:522-4. 2012
    ..In conclusion, BRCA1-mutated and/or basal-like breast cancers may benefit from treatment regimens that include elesclomol...
  3. pmc Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin
    Kedar Hastak
    Division of Oncology, Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 70:7970-80. 2010
    ..Our results suggest a novel therapeutic strategy to treat women with TN breast cancer, an aggressive disease that presently lacks effective treatment options...
  4. pmc Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase
    Elizabeth Alli
    Department of Medicine Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Cancer Res 69:3589-96. 2009
    ..The defect may be attributed, at least in part, to a novel role for BRCA1 in the BER pathway. Overall, these data offer preventive, prognostic, and therapeutic usefulness...
  5. doi request reprint A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
    Shaveta Vinayak
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Breast Cancer Res Treat 142:389-98. 2013
    ..The results are inconclusive and do not exclude a favorable effect on breast cancer risk. ..